PDGFRB and malignant peripheral nerve sheath tumor: Considering the overexpression of PDGFR-β in MPNST and in larger tumors, it seems reasonable to speculate that tyrosine kinase inhibitors (TKI) such as toceranib (Palladia®), may have a role in the treatment of the more aggressive PNST.